CoChat
Sign Up
Cited by 7CAR-T cell therapy researchMultiple Myeloma Research and TreatmentsImmunotherapy and Immune Responses

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma

Open access
Li, Hongwen, Li, Jing, Wu, Jiazhuo, Shi, Zhuangzhuang, Gao, Yuyang, Song, Wenting, Li, Jiwei, Li, Zhaoming +1 more·2023·Cancer Medicine
DOI 10.1002/cam4.5818PMC PMC10225187
Open this paper in CoChat — free account

Abstract

Background: Multiple myeloma (MM) is an aggressive plasma cell malignancy, causing a number of deaths worldwide every year. Chimeric antigen receptor (CAR) transduced T‐cell therapy has been a promising immunotherapy against hematological malignancies. Methods: In this study, we developed a second‐generation CAR construct and generated CAR‐T cells targeting CD38 molecule. Then effects of CAR‐T cells against MM cell lines were evaluated. Results: CD38‐CAR‐T cells showed higher cytotoxicity to MM cell lines and primary MM cells than that of control T cells in vitro. Over 50% MM1.s and RPMI8226 cells were killed by CAR‐T cells even at effector to target ratio of 1:100. CAR‐T cells also showed an enhanced cytotoxicity against primary MM cells. CAR‐T cells could be activated and produced a variety of cytokines in a target‐dependent manner. In vivo test indicated that CAR‐T cells also showed significant antitumor effect on xenograft mice models. Conclusion: These results indicated a promising therapeutic strategy of CD38‐CAR‐T cells against MM.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cam4.5818

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CAR-T cells targeting GPRC5D, CD19, CD38, CD138, CS1, and NKG2D are under exploration for MM treatment.

    “Several CAR-T cells targeting antigens, such an GPRC5D [229–231], CD19 [232, 233], CD38 [234–236], CD138 [237], CS1 [238–240] and NKG2D [241, 242] are also under exploration for their efficacy in MM treatment.”

    From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [236]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 27

  1. [1]Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B‐cell lymphoblastic leukemia. N Engl J Med. 2018; 378: 439‐ 448. doi: 10.1056/NEJMoa1709866 29385370 PMC5996391 · DOI · Paper page
  2. [2]Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B‐cell lymphomas. N Engl J Med. 2017; 377: 2545‐ 2554. doi: 10.1056/NEJMoa1708566 29226764 PMC5788566 · DOI
  3. [3]Raje N, Berdeja J, Lin Y, et al. Anti‐BCMA CAR T‐cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019; 380: 1726‐ 1737. doi: 10.1056/NEJMoa1817226 31042825 PMC8202968 · DOI · Paper page
  4. [4]Zhao WH, Liu J, Wang BY, et al. A phase 1, open‐label study of LCAR‐B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018; 11: 141. doi: 10.1186/s13045-018-0681-6 30572922 PMC6302465 · DOI
  5. [5]Zhang WY, Wang Y, Guo YL, et al. Treatment of CD20‐directed chimeric antigen receptor‐modified T cells in patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma: an early phase IIa trial report. Signal Transduct Target Ther. 2016; 1: 16002. doi: 10.1038/sigtrans.2016.2 29263894 PMC5661644 · DOI
  6. [6]Tan Y, Cai H, Li C, et al. A novel full‐human CD22‐CAR T cell therapy with potent activity against CD22(low) B‐ALL. Blood Cancer J. 2021; 11: 71. doi: 10.1038/s41408-021-00465-9 33839735 PMC8036232 · DOI
  7. [7]Turtle CJ, Hay KA, Hanafi LA, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19‐specific chimeric antigen receptor‐modified T cells after failure of ibrutinib. J Clin Oncol. 2017; 35: 3010‐ 3020. doi: 10.1200/JCO.2017.72.8519 28715249 PMC5590803 · DOI
  8. [10]Mikhael J, Richter J, Vij R, et al. A dose‐finding phase 2 study of single agent isatuximab (anti‐CD38 mAb) in relapsed/refractory multiple myeloma. Leukemia. 2020; 34: 3298‐ 3309. doi: 10.1038/s41375-020-0857-2 32409691 PMC7685976 · DOI · Paper page
  9. [11]Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T‐cell therapies for multiple myeloma. Blood. 2017; 130: 2594‐ 2602. doi: 10.1182/blood-2017-06-793869 28928126 PMC5731088 · DOI
  10. [12]Gagelmann N, Riecken K, Wolschke C, et al. Development of CAR‐T cell therapies for multiple myeloma. Leukemia. 2020; 34: 2317‐ 2332. doi: 10.1038/s41375-020-0930-x 32572190 · DOI
  11. [13]Danylesko I, Beider K, Shimoni A, Nagler A. Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol. 2012; 2012: 753407. doi: 10.1155/2012/753407 22649466 PMC3357929 · DOI
  12. [14]Drent E, Groen RW, Noort WA, et al. Pre‐clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica. 2016; 101: 616‐ 625. doi: 10.3324/haematol.2015.137620 26858358 PMC5004365 · DOI
  13. [15]Partida‐Sanchez S, Cockayne DA, Monard S, et al. Cyclic ADP‐ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat Med. 2001; 7: 1209‐ 1216. doi: 10.1038/nm1101-1209 11689885 · DOI · Paper page
  14. [16]Partida‐Sanchez S, Goodrich S, Kusser K, Oppenheimer N, Randall TD, Lund FE. Regulation of dendritic cell trafficking by the ADP‐ribosyl cyclase CD38: impact on the development of humoral immunity. Immunity. 2004; 20: 279‐ 291. doi: 10.1016/s1074-7613(04)00048-2 15030772 · DOI
  15. [17]Reddy M, Eirikis E, Davis C, Davis HM, Prabhakar U. Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J Immunol Methods. 2004; 293: 127‐ 142. doi: 10.1016/j.jim.2004.07.006 15541283 · DOI
  16. [18]Hosen N, Matsuoka Y, Kishida S, et al. CD138‐negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia. 2012; 26: 2135‐ 2141. doi: 10.1038/leu.2012.80 22430638 · DOI
  17. [19]Liu H, Yuan C, Heinerich J, et al. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. Leuk Lymphoma. 2008; 49: 306‐ 314. doi: 10.1080/10428190701813018 18231918 · DOI
  18. [20]Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T. Immunotherapies targeting CD38 in multiple myeloma. Onco Targets Ther. 2016; 5: e1217374. doi: 10.1080/2162402X.2016.1217374 PMC5139636 27999737 · DOI
  19. [21]Ormhoj M, Bedoya F, Frigault MJ, Maus MV. CARs in the lead against multiple myeloma. Curr Hematol Malig Rep. 2017; 12: 119‐ 125. doi: 10.1007/s11899-017-0373-2 28233151 PMC5410390 · DOI
  20. [22]Kohl U, Arsenieva S, Holzinger A, Abken H. CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications. Hum Gene Ther. 2018; 29: 559‐ 568. doi: 10.1089/hum.2017.254 29620951 · DOI
  21. [23]Zhang M, Chen D, Fu X, et al. Autologous Nanobody‐derived fratricide‐resistant CD7‐CAR T‐cell therapy for patients with relapsed and refractory T‐cell acute lymphoblastic leukemia/lymphoma. Clin Cancer Res. 2022; 28: 2830‐ 2843. doi: 10.1158/1078-0432.CCR-21-4097 35435984 · DOI
  22. [24]Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B‐cell maturation antigen is a promising target for adoptive T‐cell therapy of multiple myeloma. Clin Cancer Res. 2013; 19: 2048‐ 2060. doi: 10.1158/1078-0432.CCR-12-2422 23344265 PMC3630268 · DOI
  23. [25]Teoh PJ, Chng WJ. CAR T‐cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021; 11: 84. doi: 10.1038/s41408-021-00469-5 33927192 PMC8085238 · DOI
  24. [26]Kegyes D, Constantinescu C, Vrancken L, et al. Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient? J Hematol Oncol. 2022; 15: 78. doi: 10.1186/s13045-022-01296-2 35672793 PMC9171942 · DOI
  25. [27]Etxeberria I, Glez‐Vaz J, Teijeira A, Melero I. New emerging targets in cancer immunotherapy: CD137/4‐1BB costimulatory axis. ESMO Open. 2020; 4: e000733. doi: 10.1136/esmoopen-2020-000733 32611557 PMC7333812 · DOI
  26. [28]Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T‐cell therapy. Mol Ther Oncolytics. 2016; 3: 16011. doi: 10.1038/mto.2016.11 27626062 PMC5008265 · DOI
  27. [29]An N, Hou YN, Zhang QX, et al. Anti‐multiple myeloma activity of nanobody‐based anti‐CD38 chimeric antigen receptor T cells. Mol Pharm. 2018; 15: 4577‐ 4588. doi: 10.1021/acs.molpharmaceut.8b00584 30185037 · DOI

Cited by

Sorted by citations

Authors
Li, H., Li, J., Wu, J., Shi, Z., Gao, Y., Song, W., Li, J., Li, Z., & Zhang, M.
Affiliations
  • First Affiliated Hospital of Zhengzhou University (CN)
  • Sun Yat-sen University (CN)
  • Zhengzhou University (CN)
  • Sun Yat-sen University Cancer Center (CN)
Corresponding author
Zhang, Mingzhi
ORCID
Venue
Cancer Medicine
Publisher
Wiley
Published
2023-04-11
Volume
12
Issue
9
Pages
10804-10815
ISSN
2045-7634 (ISSN-L)
DOI
10.1002/cam4.5818
PMC
PMC10225187
OpenAlex
W4364351788
Cited by
7
References
2
Citations by year
2026: 1 · 2025: 1 · 2024: 4 · 2023: 1
FWCI
0.85
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81970184, 82070209, 82170183, U1904139)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
multiple myeloma, CD38, chimeric antigen receptor T cells, second-generation CAR, CAR T-cell therapy, T cell cytotoxicity, primary myeloma cells, cytokine production
MeSH terms
Receptors, Chimeric Antigen, Animals, Humans, Immunotherapy, Multiple Myeloma, Receptors, Antigen, T-Cell, T-Lymphocytes, Immunotherapy, Adoptive, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review